BG
IMCR icon

Bellevue Group’s Immunocore IMCR Stock Holding History

Bellevue Group’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.3M Hold
2,796,803
– – 2.01% 17
2025
Q4 		$97.1M Hold
2,796,803
– – 1.84% 18
2025
Q3 		$102M Buy
2,796,803
+354,973
+15% +$12.1M 2.11% 15
2025
Q2 		$76.6M Buy
2,441,830
+1,220,036
+100% +$37.9M 1.69% 16
2025
Q1 		$36.3M Buy
1,221,794
+16,330
+1% +$490K 0.81% 29
2024
Q4 		$35.6M Hold
1,205,464
– – 0.68% 33
2024
Q3 		$37.5M Buy
1,205,464
+50,810
+4% +$1.85M 0.61% 47
2024
Q2 		$39.1M Buy
1,154,654
+182,400
+19% +$9.3M 0.64% 48
2024
Q1 		$63.2M Sell
972,254
-3,800
-0.4% -$261K 0.96% 27
2023
Q4 		$66.7M Buy
976,054
+956,204
+4,817% +$49.7M 1.02% 29
2023
Q3 		$1.03M Buy
+19,850
New +$1.17M 0.02% 128

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Bellevue Group's IMCR Position: Q1 2026 in Review

Bellevue Group held its Immunocore (IMCR) position steady in Q1 2026 at 2,796,803 shares worth $84.3M. The position accounts for 2.01% of the portfolio, ranked #17.

Bellevue Group first reported a position in IMCR in Q3 2023 and has held it in 11 quarters since. The position peaked at $102M in Q3 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Bellevue Group held 2,796,803 shares of Immunocore worth $84.3M as of Q1 2026.
  • Bellevue Group left its Immunocore share count unchanged in Q1 2026.
  • Immunocore made up 2.01% of Bellevue Group's portfolio in Q1 2026, its #17 holding.
  • Bellevue Group first reported a position in Immunocore in Q3 2023 and has held it in 11 quarters since.
  • Bellevue Group's Immunocore position peaked at $102M in Q3 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.